As can be seen from the following set of drug safety alerts, Pradaxa has caused significant concern among doctors and patients since soon after it first became available for use in the US. In early December 2011 the FDA announced it would evaluate reports of bleeding in patients taking Pradaxa that have been submitted to the agency’s Adverse … [Read more...]
Eliquis MDL For Federal Lawsuits; In California, JCCP Petition Pending
In the federal court system, there are now more than 50 Eliquis lawsuits filed, and more of these drug injury and death cases are expected. Given this situation, in early February 2017 the United States Judicial Panel on Multidistrict Litigation (JPML) established this consolidation of all federal court Eliquis cases, IN RE: ELIQUIS (APIXABAN) … [Read more...]
Defendants BMS And Pfizer Ask For Eliquis Federal Court Consolidation
On October 13, 2016 attorneys for Bristol-Myers Squibb Company and Pfizer Inc. filed with the United States Judicial Panel on Multidistrict Litigation (JPML) this court document, “BRISTOL-MYERS SQUIBB COMPANY AND PFIZER INC.’S MOTION FOR TRANSFER OF RELATED ELIQUIS (APIXABAN) PRODUCTS LIABILITY ACTIONS FOR COORDINATED PRETRIAL PROCEEDINGS PURSUANT … [Read more...]
Is Eliquis A Safe Alternative To Warfarin For Patients On Dialysis?
In this article published online by Pharmacy Times in August 2016, “Is Apixaban Safe and Effective for Patients on Hemodialysis?”, Brandon Dyson, PharmD, BCPS, who is a clinical pharmacist at an academic medical center, puts some scrutiny on Eliquis, an increasingly popular blood-thinner drug: [Eliquis (apixaban)] is the only [novel oral … [Read more...]
No Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis (apixaban). Earlier this month the medical journal Chest published this article, “Direct comparison of dabigatran, rivaroxaban, and apixaban for … [Read more...]
Eliquis Lawsuits Being Filed Across The Country In Increasing Numbers
It is important to know that as of September 2016 Eliquis does not currently have an FDA-approved antidote, or reversal agent, for a patient experiencing a trauma-induced bleeding event or needing emergency surgery. Eliquis (apixaban) was approved by the FDA in December 2012. These serious medical conditions have been associated with the use of … [Read more...]
Antidote Drug For Xarelto / Savaysa / Eliquis Is Denied FDA Approval
The following Factor Xa inhibitors, which serve as blood-thinner drugs, are being used by an increasing number of patients for stroke prevention and for treatment of deep vein thrombosis and pulmonary embolism: Eliquis (apixaban) from Pfizer/Bristol-Myers Squibb; Xarelto (rivaroxaban) from Bayer/Johnson & Johnson; and, Savaysa … [Read more...]
New Studies Investigate Long-Term Anticoagulation Use & Bleeding Risk
According to a Patient-Centered Outcomes Research Institute (PCORI) press release from earlier this month, the PCORI Board of Governors approved $6.5 million for research to compare the potential benefits and harms of popular anticoagulant drugs. The study will include the older anticoagulant, Coumadin (warfarin), as well as the newer "novel … [Read more...]
Doctors Are Concerned About Lack Of Savaysa Antidote To Stop Bleeding
I think it is interesting how this recent Healio – HemOnc Today news reports, “Edoxaban safe, effective for extended prevention of recurrent VTE”, ends by focusing on the continuing lack of any FDA-approve antidote for Savaysa, as well as Eliquis and Xarelto. The growing availability of agents for the reversal of bleeding caused by direct oral … [Read more...]